Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.25 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 81 | 0.91 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 1723
Sealed predictions
- SEPSECS in dopamine neurons, braak+0.23 (p 0.549) → +0.46 (p 0.214)receipt 1729
Swarm cases
receipt 1729: SEPSECS in dopamine neurons, braak
- power
- full sample +0.34 (p 0.167, n 18), 95% CI -0.15 to +0.70. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.36 (p 0.148, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.40 (p 0.099, n 18). could be the mix.
- skeptic
- leave-one-out range +0.25 to +0.51, sign flips 0; without severely affected donors +0.34 (p 0.167, n 18). fragile.
- cell type
- strongest in microglia: +0.61 (p 0.0067, n 18) vs +0.34 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SEPSECS in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SEPSECS · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.20 p 0.477 (needs p < 8.6e-4)
Receipts
loading the receipts